American Society of Hirudotherapy

Molecular Insights into Leech-Derived Bioactive Compounds: Biochemical Mechanisms and Therapeutic Potential

Raghavi S, Deva Darshini B, Saravanan KM, Anbarasu K (2026) · International Journal of Molecular Sciences

Preclinical / molecular study: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Study record: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.

Study Profile

Model / material
comprehensive narrative review of leech-derived bioactive compounds with focus on biochemical mechanisms, clinical applications, and translational biotechnology challenges (Saveetha Institute of Medical and Technical Sciences and AMET University, India)
Method
Synthesis of proteomic and transcriptomic data identifying more than 100 bioactive leech salivary molecules (hirudin, calin, eglins, bdellins, destabilase, decorsin and others) and review of their biochemical roles in coagulation, inflammation, antimicrobial defense, wound healing, and angiogenesis
Main result
More than 100 bioactive molecules documented in leech saliva including hirudin, calin, eglins, bdellins, destabilase, and decorsin; mechanisms span anticoagulation, anti-inflammatory action, antimicrobial activity, antioxidant effects, and regenerative signaling; clinical applications detailed in reconstructive/microsurgical practice (venous congestion, graft success); emerging applications in wound healing, cardiovascular health, musculoskeletal conditions, regenerative medicine, drug-delivery systems (recombinant proteins, nanocarriers); biotechnology advances (recombinant production, high-throughput omics, nanotechnology) address scalability and standardization challenges

Key Findings

  • Comprehensive contemporary catalog of leech salivary bioactive molecules — more than 100 distinct compounds documented
  • Integrates biochemistry, clinical applications, and biotechnology challenges within a single review framework
  • Highlights emerging drug-delivery applications (recombinant proteins and nanocarriers) as next-generation leech-derived therapeutics
  • Identifies biological variation, infection risk, bleeding risk, and regulatory purity/standardization as key translational challenges
  • Adds Indian research perspective to the global leech-pharmacology synthesis literature

Limitations

  • Narrative review without systematic methodology or quantitative synthesis
  • No primary mechanism or clinical data generated
  • Selection of cited compounds and applications reflects authors' research interests
  • Translational biotechnology discussion may oversimplify regulatory pathway complexity for recombinant proteins
  • Does not provide GRADE-style certainty assessments for individual indications

Clinical Implications

Raghavi 2026 provides a useful contemporary synthesis bridging classical leech salivary biochemistry and emerging drug-delivery biotechnology. For ASH editorial purposes, the review is helpful contextual background on compound-registry pages and supports the editorial position that whole-leech therapy effects cannot be reduced to any single bioactive molecule. The review explicitly acknowledges the regulatory standardization challenges that affect both whole-leech device clearance (K040187) and recombinant pharmaceutical development. For US clinicians, the trial does not change practice but does provide a current reference for understanding the breadth of the leech-derived therapeutic landscape.

Related studies

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.